Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes

Brian A. Ference, Jennifer G. Robinson, Robert D. Brook, Alberico L. Catapano, M. John Chapman, David R. Neff, Szilard Voros, Robert P. Giugliano, George Davey Smith, Sergio Fazio, Marc S. Sabatine

    Research output: Contribution to journalArticle

    232 Citations (Scopus)

    Abstract

    BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive.

    Original languageEnglish (US)
    Pages (from-to)2144-2153
    Number of pages10
    JournalNew England Journal of Medicine
    Volume375
    Issue number22
    DOIs
    StatePublished - Dec 1 2016

    Fingerprint

    Cardiovascular Diseases
    LDL Cholesterol
    Confidence Intervals
    Odds Ratio
    Proprotein Convertase 9
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Genes
    Fasting
    Oxidoreductases
    Alleles
    Clinical Trials
    Glucose

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., ... Sabatine, M. S. (2016). Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. New England Journal of Medicine, 375(22), 2144-2153. https://doi.org/10.1056/NEJMoa1604304

    Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. / Ference, Brian A.; Robinson, Jennifer G.; Brook, Robert D.; Catapano, Alberico L.; Chapman, M. John; Neff, David R.; Voros, Szilard; Giugliano, Robert P.; Smith, George Davey; Fazio, Sergio; Sabatine, Marc S.

    In: New England Journal of Medicine, Vol. 375, No. 22, 01.12.2016, p. 2144-2153.

    Research output: Contribution to journalArticle

    Ference, BA, Robinson, JG, Brook, RD, Catapano, AL, Chapman, MJ, Neff, DR, Voros, S, Giugliano, RP, Smith, GD, Fazio, S & Sabatine, MS 2016, 'Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes', New England Journal of Medicine, vol. 375, no. 22, pp. 2144-2153. https://doi.org/10.1056/NEJMoa1604304
    Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. New England Journal of Medicine. 2016 Dec 1;375(22):2144-2153. https://doi.org/10.1056/NEJMoa1604304
    Ference, Brian A. ; Robinson, Jennifer G. ; Brook, Robert D. ; Catapano, Alberico L. ; Chapman, M. John ; Neff, David R. ; Voros, Szilard ; Giugliano, Robert P. ; Smith, George Davey ; Fazio, Sergio ; Sabatine, Marc S. / Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. In: New England Journal of Medicine. 2016 ; Vol. 375, No. 22. pp. 2144-2153.
    @article{5e3f136530484126930095f06b0d085b,
    title = "Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes",
    abstract = "BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95{\%} confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95{\%} CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95{\%} CI, 1.04 to 1.19) for PCSK9 and 1.13 (95{\%} CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive.",
    author = "Ference, {Brian A.} and Robinson, {Jennifer G.} and Brook, {Robert D.} and Catapano, {Alberico L.} and Chapman, {M. John} and Neff, {David R.} and Szilard Voros and Giugliano, {Robert P.} and Smith, {George Davey} and Sergio Fazio and Sabatine, {Marc S.}",
    year = "2016",
    month = "12",
    day = "1",
    doi = "10.1056/NEJMoa1604304",
    language = "English (US)",
    volume = "375",
    pages = "2144--2153",
    journal = "New England Journal of Medicine",
    issn = "0028-4793",
    publisher = "Massachussetts Medical Society",
    number = "22",

    }

    TY - JOUR

    T1 - Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes

    AU - Ference, Brian A.

    AU - Robinson, Jennifer G.

    AU - Brook, Robert D.

    AU - Catapano, Alberico L.

    AU - Chapman, M. John

    AU - Neff, David R.

    AU - Voros, Szilard

    AU - Giugliano, Robert P.

    AU - Smith, George Davey

    AU - Fazio, Sergio

    AU - Sabatine, Marc S.

    PY - 2016/12/1

    Y1 - 2016/12/1

    N2 - BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive.

    AB - BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive.

    UR - http://www.scopus.com/inward/record.url?scp=84999053643&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84999053643&partnerID=8YFLogxK

    U2 - 10.1056/NEJMoa1604304

    DO - 10.1056/NEJMoa1604304

    M3 - Article

    C2 - 27959767

    AN - SCOPUS:84999053643

    VL - 375

    SP - 2144

    EP - 2153

    JO - New England Journal of Medicine

    JF - New England Journal of Medicine

    SN - 0028-4793

    IS - 22

    ER -